Another peer-reviewed study was published this month (August 2017) showing dietary virgin coconut oil has beneficial heart-health effects regarding lipid profile, renal status, hepatic antioxidant defense system, and cardiovascular risks. The study was conducted by researchers in Nigeria in the Department of Medical Biochemistry, Faculty of Basic Medical Sciences, at Federal University. The title of the study is: Dietary Supplementation with Virgin Coconut Oil Improves Lipid Profile and Hepatic Antioxidant Status and Has Potential Benefits on Cardiovascular Risk Indices in Normal Rats. This new study and many other previous studies clearly contradict the propaganda espoused by Big Pharma and the U.S. Government dietary advice, which has been waging a war against saturated fats since the 1970s and the McGovern Report that promoted the false hypothesis that saturated fats led to an increase in lipid cholesterol levels and an increased risk for heart disease. This theory, the lipid theory of heart disease, has been shown to be false repeatedly by the published medical literature, yet it still remains the official USDA dietary advice.
The pharmaceutical empire strikes back. After the recent few years of increasing “statin deniers” getting an occasional mainstream media appearance, vested interest parties are coming up with studies to “prove” statins (cholesterol-lowering drugs) are safe. The problem is most folks on the fence, as most are, will be distracted by these studies no matter how biased and without merit they may be. Doctors who know the truth about statins are forced to pick any such statin safety study apart in response in order to straighten out doctors who prescribe statins based on pharmaceutical reps’ presentations and industry biased studies. One such doctor who is outspokenly critical of statin drugs, Scottish General Practitioner (GP) Malcom Kendrick, M.D., recently focused on a Lancet paper that intended to prove side effects from statin drugs were not only greatly exaggerated, but all in the patients' heads. According to the paper, patients were suffering from the “nocebo effect,” due to all the rising information regarding statin side effect symptoms publicly reported. In addition to his analysis of the study and comparisons to other studies, Dr. Kendrick offers his personal and professional experiences of taking patients off statins and watching them recover from torn or ravaged muscles and early onset dementia, among other side effects. Dr. Kendrick’s father, whose side effects had him wheel chair bound until his doctor-son convinced him to quit taking statins is an example he offered. No nocebo effects had them in such terrible shape that was relieved when they got off statins.
Since 2015 there have been a few pharmaceutical companies working on a new cholesterol-lowering drug type as a replacement for the older class of statin drugs, such as Lipitor. Lipitor was the best-selling drug of all time, but its patent expired a few years ago. The new mantra is getting LDL cholesterol levels lower than statin drugs. The drug class of these new cholesterol-lowering drugs is a PCSK9 inhibitor. Of course, this is madness for two reasons: (1) Cholesterol and fats, in general, are not the cause of heart disease; (2) cholesterol is vital for hormone production and nervous system and brain function. The fact is that cholesterol is vitally essential for good health, and lowering cholesterol artificially can and does lead to more immediate health problems, and a lower life expectancy. So why the focus for a new cholesterol-lowering drug? Once again, we follow the money.
There have been numerous studies on lauric acid for various health supporting factors. Did you know that virgin coconut oil is 50 percent or more lauric acid? So whatever healthy attributes lauric acid contains so does coconut oil, and more. And more will be explained later in this article. For now we’ll focus on coconut oil’s major component, lauric acid, and a recent animal study with dramatic results discovered for reducing hypertension (high blood pressure) and oxidative stress.
A 2015 study in Critical Care Medicine is titled, “Lipid Paradox in Acute Myocardial Infarction- The Association with 30-Day In-Hospital Mortality.” This study followed 724 hospitalized patients who suffered an acute heart attack (i.e., myocardial infarction). The scientists attempted to clarify the relationship between the lipid profiles and the 30-day mortality in patients who suffered a heart attack. The authors found that those with lower LDL-cholesterol and triglyceride levels had a significantly elevated mortality risk when compared to patients with higher LDL-cholesterol and triglyceride levels. Why would lowered cholesterol and triglyceride levels be associated with a higher mortality rate? Fats from triglycerides are a major energy source and LDL-cholesterol is critical for cell membrane synthesis and is needed to fight infections. Adequate LDL-cholesterol and triglyceride levels may be critical for cell function and survival in the case of a heart attack—as well as in other conditions. Folks, we have been hoodwinked to believe that we must all take cholesterol-lowering medications in order to prevent and/or treat heart disease. People do not get heart disease because their cholesterol level is elevated. Remember, 50% of patients who suffer a heart attack have normal cholesterol levels.
Cholesterol-lowering statin drugs may stimulate atherosclerosis and heart failure. Statins inhibit the synthesis of vitamin K2 in your body; vitamin K2 protects your arteries from calcification. Statins may also damage your heart by interfering with CoQ10 production, causing mitochondria damage, and interfering with selenium-containing proteins.